Safety and Effectiveness of Nimotuzumab in the Treatment of Advanced Head and Neck Cancer Patients. Phase IV Clinical Trial: Final Results
*Mayra Ramos Suzarte Department Of Molecular Microbiology And Immunology, Center Of Molecular Immunology, Cuba
*Corresponding Author: Mayra Ramos Suzarte
Department Of Molecular Microbiology And Immunology, Center Of Molecular Immunology, Cuba Email:email@example.com
Published on: 2019-03-12
Objective: Epidermal Growth Factor Receptor (EGFR) can be overexpressed in head and neck cancer (HNC). Nimotuzumab is a humanized monoclonal antibody (hMab) that binds to the EGFR. A phase IV study was conducted in advanced head and neck newly diagnosed and recurrent cancer patients to evaluate safety and efficacy of nimotuzumab.
HNC is the seventh most common cancer worldwide. This type of cancer comprises a heterogeneous group of malignant tumors that originate in the upper region of the respiratory and digestive tracts, which includes the oral cavity and lips, pharynx, larynx, salivary glands, ear, nasal cavity and paranasal sinuses. It is more evident that the oncogenesis of HNC and its evolution is characterized by profound immune defects, since cancer cells evade immunosurveillance due to the accumulation of genetic mutations and tumor heterogeneity. In the last two decades, there has been a better understanding of the underlying molecular mechanisms in HNC, and advances in molecular biology have led to the development of new targeting agents.